Warning letters, 483s, Recalls, Import Alerts, Audit observations
Centaur India formulation facility at Pune, Maharashtra, India was issued Warning letter by FDA citing
The Warning letter cite Failure of Quality unit in ensuring cGMP compliance, Inadequate control over
Centaur Pharmaceuticals, India issued Warning letter by USFDA. The Warning letter dated 5 June 2023
IPCA Dhar facility was inspected by USFDA in June 2023. The site (FEI 3007574780) was
IPCA Ratlam (India) was issued USFDA 483 with 11 observations after inspection in June 2023
USFDA Inspection at Cadila Ahmedabad, India in April-May 2019 by Investigators Justin A Boyd, Thomas
In September 2022, USFDA issued a Warning letter to Lupin API facility at Tarapur, India
Strides in July 2022 recalled from US market 1032 bottles of Prednisolone USP 20mg tablets for
